Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bleomycin (Primary) ; Bleomycin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Ifosfamide (Primary) ; Prednisone (Primary) ; Vincristine (Primary) ; Vinorelbine (Primary)
  • Indications B-cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2021 Results evaluating late severe or fatal cardiac toxicity associated with three consecutive completed COG trials AHOD0031, AHOD0831, and AHOD1331, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 09 Dec 2021 Planned End Date changed from 1 Sep 2014 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top